

## **SUPPLEMENTARY INFORMATION**

### **EXTENDED MATERIALS AND METHODS**

#### **Cell culture**

900677A (primary) and 900677AT (large T antigen immortalized) fibroblasts with a genetic deficiency for *XRCC2*, and derivative lines, and HEK293T, U2OS-DR, and GM0637 cells, were grown in Dulbecco's Modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Cells were irradiated as described previously.[1] Stock solutions of cycloheximide (10 mg/ml in H<sub>2</sub>O; Sigma), MG132 (10 mM in DMSO; Calbiochem), olaparib (10 mM in DMSO; Sigma), MMC (3 mM in 50% ethanol; Sigma), and HU (500 mM in medium; Sigma) were kept at -20°C.

#### **Cloning and mutagenesis**

Human *XRCC2* cDNA (SC116732) was purchased from Open Biosystems. The R215X mutant of *XRCC2* was generated using the QuikChange II Site-Directed Mutagenesis kit (Stratagene) according to the manufacturer's instructions.

#### **Transfection and viral transduction**

900677AT cells were reconstituted with *XRCC2* or a neomycin phosphotransferase containing control S91 gammaretroviral vector for selection with G418/geneticin, as described previously.[2 3] Alternatively, for experiments involving the R215X mutant of *XRCC2*, cells were retrovirally transduced (pOZ) with the mutant or *XRCC2*-WT along with a N-terminal Flag-HA tag and selected by IL-2 beads as described previously.[4]

### **Immunofluorescence microscopy**

Cells were grown on coverslips coated with poly-D-lysine, fixed with 2% paraformaldehyde for 20 min and permeabilized with 0.2% Triton X-100 for 3 min. Following washes with PBS, slides were incubated with primary and secondary antibodies, washed, and mounted with a coverglass, as described previously.[5]

Microscopy, collection of images, counting of three replicates per sample, and the generation of figures were as described previously.[5]

### **Immunoprecipitation**

Cells were lysed in NETN 420 buffer supplemented with protease inhibitors and PMSF as described previously.[1] Immunoprecipitations were performed with anti-Flag M2 Affinity Gel (Sigma) or specified antibodies as described previously.[1]

### **Antibodies**

The following primary antibodies were utilized: RAD51D (Novus, NB100-166, rabbit), XRCC2 (Santa Cruz, sc-5895, goat and sc-365854, mouse), BRCA1 (Millipore, 07-434, rabbit) and BRCA2 (Calbiochem, OP95, mouse). Anti-RAD51C (mouse), anti-XRCC3 (rabbit), anti- $\gamma$ H2AX (mouse), anti-HA (mouse), anti- $\beta$  actin (mouse) antibodies were as described elsewhere.[6]

Secondary antibodies for immunofluorescence microscopy included FITC conjugated donkey anti-mouse or anti-rabbit IgG and Rhodamine B-conjugated donkey anti-mouse or anti-rabbit IgG antibodies (Jackson ImmunoResearch) as described previously.[5] For

immunoblotting, signals from HRP-linked secondary antibodies (Amersham) were detected by chemiluminescence (Amersham) as previously described.[5]

### **DNA damage sensitivity assays**

For measurements of MMC, olaparib and formaldehyde sensitivity, cells were plated into 96 well plates in triplicate at  $2 \times 10^3$  cells/well. The next day, cells were treated with MMC at doses ranging from 0-400 nM, olaparib at doses from 0-4  $\mu$ M, and formaldehyde at doses from 0-80  $\mu$ M. Medium was aspirated and fresh medium without any of these DNA damage agents was added after overnight incubation, and cells were incubated an additional 3-4 days. Relative survival was measured using a colorimetric assay as described.[1]

For measurements of sensitivity to IR, 900677AT cells, with or without correction with XRCC2, were plated into 6 cm dishes in triplicate after irradiating with doses ranging from 0-8 Gy. Cells were incubated for 10 days and the number of colonies/dish was counted as described.[6]

### **Chromosome breakage analysis**

For assays of chromosome breakage in primary cells, cultures in T75 flasks in DMEM medium containing 20% fetal bovine serum, as well as penicillin-streptomycin and L-glutamine, were exposed to 0, 0.01 or 0.1  $\mu$ g/ml diepoxybutane (DEB) for 48 hr. Cells were accumulated in mitosis by treatment with 0.2 mg/ml colcemid for the last 7-8 hr. Metaphase spreads were prepared, G banded, and analyzed under a brightfield microscope.

For assays of Lg T-immortalized lines, cells were grown in a T25 flask and were treated with 300 nM MMC for 72 hr in the dark, and arrested in mitosis with a final concentration of 200

ng/ml of colcemid (Gibco) for 3 hr. Cells were collected by trypsinization, washed with medium containing serum, and treated with 50 mM KCl for 10 min at 37°C for swelling. Cells were subsequently fixed, dropped onto slides, and stained with Giemsa as described,[7] and visualized using a microscope.

The total number of aberrations per chromosome, including breaks, gaps and radials was counted as described.[8] The percent of cells with one or more radial chromosomes was also calculated. Each count consisted of 3 sets of 30 metaphases each which was utilized for a mean  $\pm$  standard deviation.

### **G2-M accumulation**

To measure G2-M accumulation, cells were treated with 0.35  $\mu$ g/ml of melphalan, fixed, stained with propidium iodide and treated with RNase A, gated, and analyzed using ModFit software as described.[4]

## **REFERENCES FOR EXTENDED MATERIALS AND METHODS**

1. Zhang F, Fan Q, Ren K, Andreassen PR. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. *Mol Cancer Res* 2009;7:1110-8.
2. Virts EL, Jankowska A, Mackay C, Glaas MF, Wiek C, Kelich SL, Lottmann N, Kennedy FM, Marchal C, Lehnert E, Scharf RE, Dufour C, Lanciotti M, Farruggia P, Santoro A, Savasan S, Scheckenbach K, Schipper J, Wagenmann M, Lewis T, Leffak M, Farlow JL, Foroud TM, Honisch E, Niederacher D, Chakraborty SC, Vance GH, Pruss D, Timms KM, Lanchbury JS, Alpi AF, Hanenberg H. AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia. *Human Mol Genet* 2015;24:5093-108.
3. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, Neveling K, Endt D, Kesterton I, Autore F, Fraternali F, Freund M, Hartmann L, Grimwade D, Roberts RG, Schaal H, Mohammed S, Rahman N, Schindler D, Mathew CG. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. *Nature Genet* 2010;42:406-9.

4. Zhang F, Fan Q, Ren K, Andreassen PR. FANCI/BRIP1 recruitment and regulation of FANCD2 in DNA damage responses. *Chromosoma* 2010;119:637-49.
5. Fan Q, Zhang F, Barrett B, Ren K, Andreassen PR. A role for monoubiquitinated FANCD2 at telomeres in ALT cells. *Nucleic Acids Res* 2009;37:1740-54.
6. Park JY, Singh TR, Nassar N, Zhang F, Freund M, Hanenberg H, Meetei AR, Andreassen PR. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair. *Oncogene* 2014;33:4803-12.
7. Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. *Genes Dev* 2004;18:1958-63.
8. Oostra AB, Nieuwint AW, Joenje H, de Winter JP. Diagnosis of fanconi anemia: chromosomal breakage analysis. *Anemia* 2012;2012:238731.